NCT07093385View on ClinicalTrials.gov

Intravitreal Faricimab in Patients With Refractory Macular Edema

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

July 1, 2025

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Faricimab Injection

Faricimab (6 mg/0.05 mL) for three months (loading dose) in a sterile environment,

Trial Locations (1)

Unknown

Baghdad university, Baghdad

All Listed Sponsors
lead

Baghdad college of medicine

OTHER

NCT07093385 - Intravitreal Faricimab in Patients With Refractory Macular Edema | Biotech Hunter | Biotech Hunter